Answers are grounded in this paper and cite their sources.
Background: Microdeletion/microduplication syndromes are rare chromosomal abnormalities causing diverse clinical features due to gene dosage imbalances caused by submicroscopic deletions/duplications (Copy Number Variations—CNVs) of contiguous genes in specific chromosomal regions. CNVs causing microdeletion/microduplication syndromes encoded in reference databases (Orphanet, OMIM) have a significant clinical impact in neurodevelopmental disorders (NDDs). Methods: A retrospective study analyzed the molecular and clinical data of 446 pediatric patients referred for suspected NDDs to the Outpatient Clinic of the Child Neuropsychiatry Unit at University Hospital of Catania Italy, between 2020 and 2024. Final clinical diagnoses reflect comprehensive post-intake evaluations. Results: Over 446 patients, 156 (35%) had CNVs in autosomal chromosomes. Thirty-nine (8.7%), 28 males (71.8%) and 11 females (28.2%), with a mean age of 11.8 years (SD: 4.6), were diagnosed with microdeletion/microduplication syndromes. Chromosome 16 (30.8%, 12/39), chromosome 22 (12.8%, 5/39), chromosome 15 (7.7%, 3/39) and chromosome 7 (7.7%, 3/39) were more frequently implicated. De novo rearrangements accounted for 23.1% of cases (9/39), while 69.2% (27/39; 11 maternal, 16 paternal) were inherited from unaffected or pauci-symptomatic parents. Direct mapping to OMIM or Orphanet database entries was present in 22 patients (56.4%). The neurobehavioral phenotype was dominated by intellectual disability (ID)/developmental delay (DD) (26 patients, 66.7%), dysmorphic features (18 patients, 46.2%) and autism spectrum disorder (ASD) (15 patients, 38.5%), followed by developmental coordination disorder (10 patients, 25.6%), Specific Language Disorder/Communication Disorder (SLD) (10 patients, 25.6%), Disruptive behavioral disorders (7 patients, 17.9%), ADHD (4 patients, 10.3%), microcephaly (3 patients, 7.7%), structural brain MRI abnormalities (3 patients, 7.7%), epilepsy (3 patients, 7.7%) EEG abnormalities (2 patients, 5.1%) and selective mutism (2 patients, 5.1%). The cumulative clinical burden ranged from 1 to 6 manifestations per patient (median: 2, IQR: 2–3), with 82.1% of patients presenting with 2–3 co-occurring features. Conclusions: The identification of CNVs syndromes and associated clinical phenotypes is of significant support in the diagnostic process and possible therapeutic management. ID and ASD represent the core diagnostic drivers, while the high rate of inherited CNVs and multi-domain comorbidity underscore the impact of variable expressivity and cumulative clinical burden in neurodevelopmental disorders.
No takes yet. Share an insight, caveat, or question.
Randazzo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: